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Abstract
Objectives To evaluate the efficacy and safety of intravenous iron,
focusing primarily on its effects on haemoglobin, requirement for
transfusion, and risk of infection.
Design Systematic review and meta-analysis of randomised controlled
trials investigating the safety and efficacy of intravenous iron therapy.
Data sourcesRandomised controlled trials fromMedline, Embase, and
the Cochrane Central Register of Controlled Trials from 1966 to June
2013, with no language restrictions.
Eligibility criteria for selecting studies Eligible trials were randomised
controlled trials of intravenous iron compared with either no iron or oral
iron. Crossover and observational studies were excluded.
Main outcome measures Change in haemoglobin concentration and
risk of allogeneic red blood cell transfusion (efficacy) and risk of infection
(safety).
ResultsOf the 75 trials meeting the inclusion criteria, 72 studies including
10 605 patients provided quantitative outcome data for meta-analysis.
Intravenous iron was associated with an increase in haemoglobin
concentration (standardised mean difference 6.5 g/L, 95% confidence
interval 5.1 g/L to 7.9 g/L) and a reduced risk of requirement for red
blood cell transfusion (risk ratio 0.74, 95% confidence interval 0.62 to
0.88), especially when intravenous iron was used with erythroid
stimulating agents (ESAs) or in patients with a lower baseline plasma
ferritin concentration. There were no significant interactions between
the efficacy of intravenous iron and type or dose administered.
Intravenous iron was, however, associated with a significant increase
in risk of infection (relative risk 1.33, 95% confidence interval 1.10 to
1.64) compared with oral or no iron supplementation. The results
remained similar when only high quality trials were analysed.
Conclusions Intravenous iron therapy is effective in increasing
haemoglobin concentration and reducing the risk of allogeneic red blood
cell transfusion and could have broad applicability to a range of acute
care settings. This potential benefit is counterbalanced by a potential
increased risk of infection.
Introduction
Iron is essential for the production of red blood cells and is the
most common nutritional deficiency worldwide, both in
developed and developing countries.1 Though allogeneic red
blood cell transfusion might be lifesaving for the management
of acute severe blood loss, there are increasing concerns about
associated serious adverse events, costs, and scarcity.2 Safe and
effective strategies to reduce such transfusions are urgently
needed.
Correction of iron deficiency anaemia with oral iron is limited
by gastrointestinal absorption and is particularly ineffective in
the setting of coexisting acute or chronic medical conditions.3
Supported by laboratory results, intravenous iron therapy has
an established role in the treatment of iron deficiency anaemia,
when oral preparations are ineffective or cannot be used.4Recent
advances in the understanding of iron metabolism and the
association between allogeneic red blood cell transfusion and
adverse outcomes has increased the interest in the use of
intravenous iron to reduce requirement for red blood cell
transfusion in various acute clinical settings.5 6 Although older
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intravenous iron preparations were associated with a risk of
anaphylaxis, newer preparations have largely alleviated this
problem.7 Nevertheless, whether intravenous iron is associated
with other important adverse events, in particular the theoretical
risk of infection, remains uncertain.8-10
In this systematic review and meta-analysis, undertaken
according to PRISMA guidelines,11we evaluated the safety and
efficacy of intravenous iron, focusing primarily on its effects
on requirement for transfusion and risk of infection.
Methods
Eligibility criteria
We searched for randomised controlled trials in which
intravenous iron was compared with either oral iron or no iron
supplementation. Studies were excluded if theywere randomised
but with a crossover design, observational, did not report an
outcome of interest, provided insufficient data for outcomes to
be reported, or did not contain a group or subgroup in which
the independent effect of intravenous iron could be assessed.
The primary outcomes of interest were change in haemoglobin
concentration and risk of transfusion (efficacy) and risk of
infection (safety). Secondary outcomes of interest included
adverse events and serious adverse events as defined by the
primary studies, anaphylaxis, mortality, length of hospital stay,
cost, and cost effectiveness.
Search strategy
The primary search was conducted with Medline, Embase and
the Cochrane Central Register of Controlled Trials for
randomised trials with the terms “iron” and “ferric compounds”
and “intravenous.” The search included the time period from
1966 to June 2013 and was conducted without language
restrictions. We searched the reference lists of all included
studies as well as relevant review articles and conference
proceedings. Themanufacturers of intravenous iron formulations
were also contacted to request access to unpublished trial data.
Two authors (EL and JX) independently conducted the primary
search. When we were uncertain about eligibility or needed
additional data on endpoints, we contacted the corresponding
author to request further information.
Study selection
Two authors (EL and JX) retrieved potentially relevant titles
for full text review and transcribed data from eligible studies
onto a prespecified proforma. Studies that were published only
in abstract formwere excluded. Disagreement on study inclusion
or endpoints was resolved by the third author (KMH).
Data analysis
Our primary outcomes of interest were efficacy (change in
haemoglobin concentration and proportion of patients requiring
allogeneic red blood cell transfusion) and safety (all cause
infection). When studies included both oral iron and no iron
comparison groups, we preferentially compared intravenous
iron with oral iron. For categorical data, the risk of an outcome
was defined as the number of patients with an event compared
with the number of patients with and without an event. For
continuous data, we used mean, standard deviation, and
participant number. Data from studies fulfilling the eligibility
were pooled for meta-analysis with a random effects model.
Studies with no events in one of the study groups were included
as this has been shown to provide a more valid estimate of true
treatment effect.12 We calculated standardised mean difference
and risk ratio with 95% confidence interval for continuous and
categorical outcomes, respectively, and P<0.05 was taken as
significant. Heterogeneity was assessed with the I2 statistic, and
I2>40% was considered as significant heterogeneity.
Meta-regression was undertaken to examine the effect of
intravenous iron dose and baseline iron on the associations
between intravenous iron and the primary outcomes.
We carried out a sensitivity analysis on the efficacy (transfusion)
and safety (infection) outcomes by excluding studies with a
high risk of bias for one or more key domains using the
Cochrane Collaboration’s tool for assessing risk of bias.13
Publication bias was assessed with a funnel plot, plotting the
odds ratio for proportion transfused against the standard error
of the log odds ratio. The statistical analysis was conducted with
Stata (Intercooled Version 11.2, StataCorp, College Station,
TX, USA) and ComprehensiveMeta-analysis (version 2.2.034,
Biostat, USA, 2006).
Results
The initial electronic search returned 1815 citations. After
examination of the titles and abstracts, we retrieved 126 for
more detailed examination. A total of 75 studies including 10
879 participants fulfilled the inclusion criteria and were included
in the systematic review (appendix 1).14-88 Of the included
studies, 72 including 10 605 participants provided sufficient
quantitative outcome data to be included in the primary
meta-analyses. Figure 1 show details of study inclusion⇓.
Study characteristics and validity assessment
The number of participants in the included studies varied
between 25 and 507, and studies were carried out in a wide
range of clinical specialties (renal n=19, obstetric n=19, surgical
n=11, oncology/haematology n=11, cardiology n=4,
gastroenterology n=4, other n=7). The baseline haemoglobin
concentration (mean range 60-145 g/L) and ferritin concentration
(mean range ferritin 70-7610 ng/mL), of the included patients
also varied between studies. The most common intravenous
iron preparation used in the included studies was iron sucrose
(n=42), followed by iron gluconate (n=10) and ferric
carboxymaltose (n=10). Dextran iron was used in seven studies;
six further studies used other iron preparations. Efficacy
outcomes, including change in haemoglobin concentration and
transfusion, were variably reported, as were safety outcomes
including infection, mortality, serious adverse events, and
anaphylaxis. Appendix 1 shows the characteristics of the
included studies.
Overall, the risk of bias was low for 18 studies and high for 57
studies. The overall high risk of bias was accounted for by most
studies not being blinded to participants or study personnel
(n=56).
The authors of nine studies provided addition data for inclusion
in the systematic review. Appendix 2 shows the results of the
validity assessment.
Quantitative data synthesis
Change in haemoglobin concentration and
proportion of patients requiring allogeneic red
blood cell transfusion
A total of 59 studies comprising 7610 participants reported the
change in haemoglobin concentration before and after treatment
(appendix 3). When data were pooled, intravenous iron was
associated with a significant increase in standardised mean
haemoglobin concentration (6.5 g/L, 95% confidence interval
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5.1 g/L to 7.9 g/L) compared with oral iron or no iron
supplementation (fig 2⇓). There was significant heterogeneity
between the studies (I2=87.7%, P<0.01).
A total of 22 studies comprising 3321 participants reported on
the risk of requiring allogeneic red blood cell transfusion.
Intravenous iron therapy was associated with a significant
reduction in risk (risk ratio 0.74, 95% confidence interval 0.62
to 0.88), without significant heterogeneity (I2=9%, P=0.3; fig
3⇓).
There was a potential interaction between use of erythroid
stimulating agents and the effect of intravenous iron therapy,
with a greater effect of intravenous iron on reducing risk of
requiring transfusion with concurrent use of erythroid
stimulating agents (slope of the regression line 0.32, 95%
confidence interval 0.02 to 0.63; P=0.04; fig 4⇓). Similarly, a
lower baseline ferritin concentration was associated with greater
therapeutic effect in reducing the risk ratio of requiring red
blood cell transfusion after intravenous iron therapy (slope of
the regression line 0.002, 95% confidence interval 0.002 to
0.004; P=0.04). There was, however, no interaction between
baseline transferrin saturation and risk of requiring red blood
cell transfusion after intravenous iron therapy.
Effect of intravenous iron on all cause infection
After we excluded three studies with no events in both
intervention and comparison groups,45-74 24 studies (n=4400)
reported data on risk of infection after intravenous iron
compared with either oral iron or no iron supplementation
(appendix 3). Intravenous iron was associated with a significant
increase in risk of infection of 1.33 (95% confidence interval
1.10 to 1.64; figure 5⇓), with no significant heterogeneity
(I2=22.7%, P=0.2).
Increased risk of infection was observed in studies comparing
intravenous iron with oral iron and in those comparing
intravenous iron with no iron. There was no interaction between
baseline ferritin, transferrin saturation, iron per dose, or erythroid
stimulating agents and risk of infection.
Effect of intravenous iron therapy on other safety
endpoints
There was no significant difference in mortality (risk ratio 1.1,
95% confidence interval 0.8 to 1.5) or serious adverse events
(1.1, 0.9 to 1.2) with intravenous iron therapy in 20 and 19 trials,
respectively. Adverse events were also not significantly different
between intravenous iron therapy and oral iron or no
supplemental iron (0.9, 0.8 to 1.1). Of the 32 studies that on
reporting anaphylaxis, there were eight cases in participants
receiving intravenous iron (n=2186).
Sensitivity analysis and publication bias
Exclusion of studies with high risk of bias according to the
Cochrane Collaboration’s tool for assessing risk of bias13 limited
the meta-analysis of risk of transfusion to only five studies
(n=901),34-78 and this did not change the direction of the
association between intravenous iron and risk of requiring
allogeneic red blood cell transfusion, but the association was
no longer significant (risk ratio 0.8, 95% confidence interval
0.6 to 1.1; P=0.66). The sensitivity analysis for risk of infection
limited the meta-analysis to eight studies20-78 and did not
substantially change the direction and magnitude of the
association between intravenous iron therapy and risk of
infection (1.4, 1.0 to 1.8; P=0.03). There was no evidence of
publication bias in reporting requirement for allogeneic red
blood cell transfusion in the pooled studies (fig 6⇓).
Discussion
In this large systematic review and meta-analysis assessing
safety and efficacy in patients in many specialties we have
shown that intravenous iron is effective in increasing
haemoglobin concentration and reducing the risk of allogeneic
red blood cell transfusion but is associated with an increased
risk of all cause infection. Intravenous iron is increasingly
advocated to treat anaemia with the aim of reducing the need
for allogeneic red blood cell transfusion; the risks and benefits
of intravenous iron, however, remain uncertain.
Reducing requirement for allogeneic red
blood cell transfusion
Allogeneic red blood cell transfusion is associated with an
increased risk of serious adverse events, including mortality.89
In this meta-analysis, we confirmed that intravenous iron is
effective in reducing the requirement for red blood cell
transfusion and thereby reducing associated risk. This benefit
seemed consistent across different categories of disease and
formulations of intravenous iron and was present whether
intravenous iron was compared with oral iron or no iron. These
findings are in keeping with recent advances in the
understanding of iron metabolism; intravenous iron is more
effective than oral iron, particularly in the setting of acute or
chronic inflammation, by bypassing the effects hepcidin—an
inhibitor of gastrointestinal iron absorption.90 As such,
intravenous iron might have an important role in the
management of patients as part of a strategy to reduce
requirement for allogeneic red blood cell transfusion for many
patients in hospital.
Additionally, we have shown that the effect of intravenous iron
on the risk of requiring allogeneic red blood cell transfusion
can be further enhanced by concomitant use of erythroid
stimulating agents. None of the studies included in the
transfusion meta-analysis were conducted in patients with
chronic renal failure, in whom use of erythroid stimulating
agents is standard. The use of these agents alone could induce
a state of functional iron deficiency and has been postulated as
a potential mechanism for the negative results of previous
studies on use of erythroid stimulating agents in critical care.91 92
Whether the addition of intravenous iron to erythroid stimulating
agents in this setting is beneficial requires further investigation.
Iron and risk of infection
The reduction in allogeneic red blood cell transfusion must be
considered alongside our finding of an increased risk of all cause
infections after intravenous iron therapy. Free iron has been
shown to potentiate bacterial growth in vitro.8Clinical evidence
on the association between intravenous iron therapy and
infection, however, has been inconclusive, with no increase in
infection observed with intravenous iron therapy in patients
undergoing dialysis or in patients after surgery or in a mouse
model of critical care anaemia.9-94 This discrepancy might be
explained by the low free iron concentrations associated with
newer intravenous iron preparations.95 96Our finding might also
be a false positive result. Infection was not a predefined endpoint
in many pooled studies, and it is possible that missing data could
have created unmeasured bias in our analysis. Furthermore, we
could not find a significant association between iron dose and
risk of infection, and, overall, serious adverse events and
mortality were not significantly increased in those receiving
intravenous iron compared with oral or no iron. Until
randomised controlled trials of intravenous iron adequately
powered for patient centred outcomes are available, including
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standardised definitions for infection, it might be preferable to
use intravenous iron preparations associated with relatively low
free iron concentrations.
Although this was a large comprehensive systematic review,
several limitations bear consideration. Firstly, data on all
outcomes were not available from each study, and the doses
and preparations of intravenous iron used in the pooled studies
varied. Nevertheless, heterogeneity in the risk of requiring
transfusion and infection was low, and the number of studies
available was sufficient to conduct several meta-regression
analyses to assess the interaction between different predictors
and efficacy of intravenous iron therapy in increasing
haemoglobin concentration. Previous smaller systematic reviews
of intravenous iron therapy were unable to provide sufficient
data to estimate important outcomes such as risk of infection
or to assess the effect of different predictors on efficacy.97 98
Secondly, the quality of the included studies was variable, and
the overall risk of bias in the included studies was high, despite
exclusion of studies that had not been published in full. Finally,
meta-regression of trial characteristics with participant level
characteristics, such as baseline ferritin concentration, could
lead to aggregation bias and might be underpowered to detect
true differences, such as the effect of type and dose of
intravenous iron.99 We included a large number of studies and
conducted meta-regression only when heterogeneity was low
on forest plot based on an a priori defined criterion of
non-significant heterogeneity (I2<40%), which reduces but
cannot completely exclude the risk of bias.
Conclusion
Intravenous iron therapy is associated with a significantly
reduced risk of need for an allogeneic red blood cell transfusion.
These findings suggest that intravenous iron might have broad
applicability to many patients in hospital, in whom anaemia is
common. This benefit is counterbalanced by a potential
increased risk of infection. Further randomised controlled trials
of intravenous iron are required to define whether it should be
used as a first line treatment to reduce allogeneic red blood cell
transfusions in patients in hospital. Such trials should include
well defined infection endpoints and be adequately powered for
important patient centred endpoints including mortality and
major morbidity.
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What is already known on this topic
Intravenous iron therapy is effective at increasing haemoglobin concentration in patients with iron deficiency anaemia
What this study adds
Intravenous iron therapy can effectively reduce the need for red blood cell transfusion across a range of acute care settings
The benefit of intravenous iron in increasing haemoglobin concentration was seen when compared with both oral iron and no iron
supplementation and was more effective when used with erythroid stimulating agents and in patients with lower baseline plasma ferritin
concentrations
Intravenous iron therapy was associated with an increased risk of infection
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Figures
Fig 1 Flow diagram of selection of studies on intravenous iron therapy
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Fig 2 Standardised mean difference in haemoglobin (g/L) in patients who received intravenous iron compared with oral
iron and no iron. Weights are from random effects analysis
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Fig 3 Risk of red blood cell transfusion in patients who received intravenous iron compared with oral iron and no iron.
Weights are from random effects analysis
Fig 4 Regression of erythroid stimulating agent on log risk ratio of red blood cell transfusion. Slope of regression line 0.32,
95% confidence interval 0.02 to 0.63; P=0.04)
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Fig 5 Risk of infection in patients who received intravenous iron. Weights are from random effects analysis
Fig 6 Odds ratio of transfusion against standard error of log odds ratio
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